STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Feb. 29, 2024	Feb. 28, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,335,431)	$ (916,292)
Adjustments to reconcile net loss to net cash used by operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	799,879	654,291
Changes in operating assets and liabilities
Prepaids		279
Accounts payable	(3,560)	12,570
Accrued liabilities	15,332	(364)
NET CASH USED BY OPERATING ACTIVITIES	(523,780)	(249,516)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	524,156	247,068
NET CASH PROVIDED BY FINANCING ACTIVITIES	524,156	247,068
NET INCREASE (DECREASE) IN CASH	376	(2,448)
CASH AT BEGINNING OF PERIOD	934	3,382
CASH AT END OF PERIOD	$ 1,310	$ 934